Compass Pathways (CMPS) stock gains as Evercore ISI upgraded the company on the latest Phase 3 trial data for the company's ...

治疗抑郁症，新型药物3期临床结果积极 Compass ...

Compass Pathways stock reversed higher Tuesday on positive test results for its psychedelic drug in treatment-resistant depression.

Compass Pathways plc upgraded to Strong Buy after phase 3 COMP360 TRD data & fast-track FDA NDA review; see catalysts, ...

Compass Pathways Plc shares fell almost 10% Tuesday after a pivotal study of its experimental psilocybin-based therapy ...

Participants received a single dose of either 25 mg of COMP360 or placebo On track for disclosure of top-line 6-week primary endpoint results in late June LONDON & NEW YORK--(BUSINESS WIRE)--Compass ...

Compass Pathways has announced six‑month results from its second phase 3 trial of COMP360, its synthetic formulation of ...

Compass Pathways plc CMPS on Wednesday reported 26-week results from Part B of its Phase 3 COMP006 trial, reinforcing the ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the 26-week results (Part B) from its second ongoing ...

New 26-week data from the phase 3 COMP006 study validate the long-term durability, safety, and remission potential of a 2-dose COMP360 psilocybin regimen for highly chronic, treatment-resistant ...

Shares of Compass Pathways climbed after the company said data from a late-stage trial of its drug for treatment-resistant depression confirmed its rapid onset and durable profile. The stock jumped 8.

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has ...